Literature DB >> 32502638

Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19.

Sida Jiang1, Qiuji Cui1, Bingwei Ni1, Yingying Chen1, Ying Tan2, Weiping Chen3, Yu Zong Chen4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32502638      PMCID: PMC7265832          DOI: 10.1016/j.phrs.2020.104989

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


× No keyword cloud information.
There have been debates and investigations on the clinical benefit and adverse effects of the traditional Chinese medicines used for the treatment of COVID-19 [[1], [2], [3]]. The answers to these questions require a more comprehensive mechanistic understanding and clinical evaluation of these traditional medicines. As part of the efforts for probing these questions, the possible mechanisms of these traditional Chinese medicines have been studied based on the experimental and predicted targets of the chemical ingredients, which have been derived from the liquid chromatograph-mass spectrometry [4] and obtained from literature surveys [5,6]. These studies have shown that the knowledge of the chemical ingredients of the traditional Chinese medicines are highly useful for COVID-19 investigations. In particular, the knowledge and clinical profiling of the activities of the chemical ingredients enables the multi-omics studies for finding the clinically-relevant targets [3], and the molecular structures of the chemical ingredients are needed for molecular docking and target binding studies in target assessment [5]. Additionally, the knowledge of the chemical ingredients facilitates the molecular and disease network analysis with respect to the experimental and predicted targets for understanding the network pharmacology [4], and the statistical frequency of appearance analysis of the literature-reported chemical ingredients and mechanisms for focusing on the high confidence mechanisms [6]. The mechanisms of the traditional Chinese medicines are multifaceted in general and for the treatment of COVID-19 in particular [1,2,5,6]. Therefore, more comprehensive investigations are needed for understanding the mechanisms of these traditional Chinese medicines, and for unveiling their benefits and adverse effects. A key step towards such investigations is to obtain the chemical ingredients of these traditional Chinese medicines, particularly the molecular structures and activities. In addition to the literature surveys [5,6], it is of interest to explore the rich resources of the open-access natural product (NP) and traditional medicine databases for the relevant information, particularly the molecular structures of the chemical ingredients and the activity-related information useful in the investigations of the traditional Chinese medicines against COVID-19. Two open questions can be raised: to what extent these databases provide the molecular structures of the chemical ingredients of the traditional Chinese medicines used for the treatment of COVID-19, and what activity-related information is provided for facilitating the mechanistic investigations. These questions were probed by a database search investigation with respect to 24 traditional Chinese medicines recommended by the National Health Commission of China [1,3,6], using the names of the constituent herbs of each medicine. The searched NP databases include SuperNatural II, UNPD, ZINC, and NPB (http://www.npbdb.net:8080) databases, which provide comprehensive molecular structures, physicochemical properties, vendors, annotations (e.g. literature reported activities and mechanisms), and predicted properties (e.g. toxicity classes) for 325,000, ∼229,000, ∼80,000 and ∼444,669 NPs respectively. The searched traditional Chinese medicine databases include TCM-ID, TCM@Taiwan, TCMID, TCMSP and SymMap with ∼7,400, ∼33,000, ∼18,200, ∼13,000 and ∼19,595 NPs respectively, which provide comprehensive information on the molecular structures of the chemical ingredients, constituent herbs, prescriptions, and activity information (e.g. experimental and predicted targets or activities, NP-target relationships, and the clinical gene expression profiles of the NP targets). Moreover, a database TM-MC (∼24,000 NPs) provides comprehensive data on the traditional medicines from Northeast Asia (Korean, Chinese, and Japanese). Our search results (Table 1 ) showed that most of the searched NP databases provide insufficient species information for searching the chemical ingredients of the traditional Chinese medicines, with the exception of the NPB database. The NPB database provides species information for 10 disciplines and the molecular structures for ∼444,669 NPs. All major traditional medicine databases support the convenient search and provide molecular structure and activity-related information for high numbers of the chemical ingredients of the 24 traditional Chinese medicines, with the exception of the TCM@Taiwan database that has been inaccessible during our search investigation. Significantly, each of these databases covers the molecular structures of 49-3,869 chemical ingredients for each traditional Chinese medicine (Table 1). In particular, the NPB database provides the molecular structures of the highest numbers of chemical ingredients for 91.7 % of the 24 traditional Chinese medicines.
Table 1

The traditional Chinese medicines (TCMs) recommended by the National Health Commission of China, the number of chemical ingredients of each TCM searchable from the major databases of traditional medicines and natural products, and the main features of each database useful for mechanistic investigations.

COVID-19 clinical casesTraditional medicine for COVID-19 treatmentDatabase
TCM-IDTCMIDTCMSPTM-MCSYMMAPNPB
Database main features useful for COVID-19 investigations
Integrated TCM data, exp targets, clinical target profileIntegrated TCM data, exp and predicted targets, activities, diseasesTCM systems pharmacology data, exp and predicted targets, target and disease networksNorth eastern Asia traditional medicinesIntegrated TCM data, symptoms, exp and predicted targets, networks of herbs, symptoms, targets and diseasesLargest natural product database for 10 disciplines, predicted targets or activities
Number of chemical ingredients in database
Medical observation period
Fatigue with gastro-intestinal discomfortHuoxiang Zhengqi capsules藿香正气胶囊7789071045135017452,347
Fatigue with feverLianhua Qingwen capsules连花清瘟胶囊7337901312160516273084
Jinhuaqinggan granula金花清感颗粒496819834109711802215
Shufengjiedu capsules疏风解毒胶囊4735711004132210411762
Clinical treatment period
Mild casesHanshi Yufei Formula寒湿郁肺证处方74310551256172414132042
Shire Yunfei Formula湿热蕴肺证处方6689301274145415412699
General casesShidu Yufei Formula湿毒郁肺证处方5496281021138612472185
Hanshi Zufei Formula寒湿阻肺证处方561836840107110661170
Severe casesHuashi Baidu Formula化湿败毒方7388631213142514812572
Qiying Liangfan Formula气营两燔证处方46367177096110501688
Xiyanping Injection喜炎平注射液5576499589179
Critical casesSuhexiang pill苏合香丸45779669310278731596
Angongniuhuang pill安宫牛黄丸2584565055856091102
Neibi Waituo Formula内闭外脱证处方347451463574423627
Shenfu Injection参附注射液76113137174491597
Shengmai Injection生脉注射液219237200240644590
Shenmai Injection参麦注射液856274106249349
Recovery periodFeipi Qixu Formula肺脾气虚证处方555745833109114401956
Qiyin Liangxu Formula气阴两虚证处方7058551064135815022570
Mild, general, severe and critical casesQingfeipaidu decoction清肺排毒汤100112421850222121043869
Severe and critical casesXuebijing Injection血必净注射液4166227287921064868
Xingnaojing Injection醒脑静注射液146303328346361451
Reduning Injection热毒宁注射液2273424215166881029
Tanreqing Injection痰热清注射液2362754826215231201
The traditional Chinese medicines (TCMs) recommended by the National Health Commission of China, the number of chemical ingredients of each TCM searchable from the major databases of traditional medicines and natural products, and the main features of each database useful for mechanistic investigations. These databases also provide a variety of the activity-related information useful for mechanistic investigations (Table 1). Specifically, TCM-ID provides experimental targets and the clinical gene expression profiles of the targets. TCMID gives experimental targets and predicted targets (by chemical structure similarity), activity values, and the profiles of the related drugs and diseases. TCMSP includes the experimental targets and predicted targets (by SysDT software), and the derived ingredient-target networks and associated target-disease networks. SymMap gives the experimental targets and predicted targets (by SysDT software), and the ring networks of herbs, TCM symptoms, modern medicine (MM) symptoms, ingredients, targets and diseases. NPB provides the predicted targets or activities (by chemical structure similarity). Collectively, these traditional medicine and natural product databases are highly useful sources of the chemical ingredient data and activity information for facilitating the mechanistic investigations of the traditional medicines against COVID-19. Author contributions Qiuji Cui, Bingwei Ni, Yingying Chen developed NPB database, Sida Jiang and Yin Tan analyzed traditional medicine data, Yu Zong Chen directed the research, Yu Zong Chen and Weiping Chen designed this work and wrote the manuscript.

Declaration of Competing Interest

The authors state no conflict of interest and have received no payment in preparation of this manuscript.
  6 in total

Review 1.  A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).

Authors:  Fangfang Huang; Ying Li; Elaine Lai-Han Leung; Xiaohua Liu; Kaifeng Liu; Qu Wang; Yongqi Lan; Xiaoling Li; Haibing Yu; Liao Cui; Hui Luo; Lianxiang Luo
Journal:  Pharmacol Res       Date:  2020-05-20       Impact factor: 7.658

2.  The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good.

Authors:  Paul E Gray; Yvonne Belessis
Journal:  Pharmacol Res       Date:  2020-04-03       Impact factor: 7.658

3.  Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study.

Authors:  Ruocong Yang; Hao Liu; Chen Bai; Yingchao Wang; Xiaohui Zhang; Rui Guo; Siying Wu; Jianxun Wang; Elaine Leung; Hang Chang; Peng Li; Tiegang Liu; Yi Wang
Journal:  Pharmacol Res       Date:  2020-04-29       Impact factor: 7.658

Review 4.  Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).

Authors:  Yu-Feng Huang; Chen Bai; Fan He; Ying Xie; Hua Zhou
Journal:  Pharmacol Res       Date:  2020-05-21       Impact factor: 7.658

5.  The pros and cons of traditional Chinese medicines in the treatment of COVID-19.

Authors:  Yali Wang; Xian Zeng; Yufen Zhao; Weiping Chen; Yu Zong Chen
Journal:  Pharmacol Res       Date:  2020-05-03       Impact factor: 7.658

6.  Corrigendum to "Traditional Chinese medicine for COVID-19 treatment" [Pharmacol. Res. 155 (2020) 104743].

Authors:  Jun-Ling Ren; Ai-Hua Zhang; Xi-Jun Wang
Journal:  Pharmacol Res       Date:  2020-03-25       Impact factor: 7.658

  6 in total
  4 in total

Review 1.  Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.

Authors:  Chang Li; Lin Wang; Linzhu Ren
Journal:  Virus Res       Date:  2020-06-24       Impact factor: 3.303

2.  The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19.

Authors:  Yu-Xi Huang; Wen-Xiao Wang; Sai Zhang; Yu-Ping Tang; Shi-Jun Yue
Journal:  Pharmacol Res       Date:  2020-06-23       Impact factor: 7.658

3.  Deciphering the Pharmacological Mechanisms of Ma Xing Shi Gan Decoction against COVID-19 through Integrating Network Pharmacology and Experimental Exploration.

Authors:  Qianqian Li; Chen Bai; Ruocong Yang; Weiying Xing; Xiaohan Pang; Siying Wu; Shaoyang Liu; Jianxin Chen; Tiegang Liu; Xiaohong Gu
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

Review 4.  Potential of algal metabolites for the development of broad-spectrum antiviral therapeutics: Possible implications in COVID-19 therapy.

Authors:  Rimjhim Sangtani; Atreyee Ghosh; Hem C Jha; Hamendra Singh Parmar; Kiran Bala
Journal:  Phytother Res       Date:  2020-11-18       Impact factor: 6.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.